Augmentin suspension price comparisons in the United States depend on more than the name of the antibiotic. Standard Augmentin oral suspension contains amoxicillin and clavulanate potassium and is supplied as powder for reconstitution. The FDA identifies four conventional concentrations: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL of prepared liquid. These formulations differ in active-component amounts and ratios, so a quotation for one concentration cannot be treated as the price of another. The prescribed final volume and whether the pharmacy is supplying original brand Augmentin or an approved generic also matter.
Bottle size is particularly important for liquid antibiotics. The FDA labeling identifies final prepared volumes of 50, 75, 100 or 150 mL across the four standard suspension families, with the available sizes varying by concentration. A labeled 100 mL bottle refers to the final prepared suspension volume, not the amount of water used for reconstitution. Pharmacy quotations may also reflect the quantity dispensed, product sourcing, handling arrangements and cash, discount or insurance terms. These factors can create different prices for seemingly similar amoxicillin/clavulanate liquid listings without establishing that the products are interchangeable.
For patients and caregivers comparing an existing prescription, the practical task is to verify the complete concentration pair, prescribed quantity, actual brand or generic product, and whether the quotation includes pharmacy preparation and any required measuring device. This evergreen guide explains how to compare those details without displaying potentially outdated retail amounts. The Augmentin oral suspension guide provides the full product catalog and preparation information, while brand Augmentin pricing and generic amoxicillin/clavulanate pricing cover the broader commercial distinctions.
Augmentin oral suspension is a prescription combination antibiotic containing amoxicillin and clavulanate potassium. Its retail cost depends on the exact liquid concentration, amount dispensed, product identity, pharmacy and payment method. A generic amoxicillin/clavulanate suspension may be offered under a different commercial arrangement from original branded Augmentin, even when the corresponding approved product strength is the same.
Liquid prescriptions differ from conventional tablets because the product is supplied as powder that must be correctly prepared before use. Pharmacy handling and dispensing arrangements may affect the quoted charge. However, preparation should not be described as a universal separate fee; whether an additional amount is charged depends on the pharmacy and payment terms.
The concentration and volume are separate variables. The concentration identifies how much amoxicillin and clavulanic acid is present in 5 mL of prepared medicine. The bottle volume identifies how much prepared suspension the package contains. A price comparison that omits either field may combine products that are not alike.
The pharmacy may also use different product records for original branded suspension, an independently approved generic or a repackaged presentation. An NDC can help identify a particular listed product or package, but it does not independently prove that the product is FDA-approved or currently available at a particular pharmacy.
This page focuses on how liquid packaging and dispensing affect price comparisons. The amoxicillin/clavulanate guide explains the combination medicine, while the Augmentin brand overview introduces the complete product family.
The FDA's July 2026 prescribing information identifies four standard Augmentin oral suspension strength pairs. Each concentration is expressed as milligrams of amoxicillin and clavulanic acid per 5 mL after reconstitution. A pharmacy listing that says only 400 mg/5 mL or 250 mg/5 mL omits the second active-component quantity and should be checked against the complete product label.
The 125 mg/31.25 mg and 250 mg/62.5 mg per 5 mL concentrations have 4:1 amoxicillin-to-clavulanic-acid ratios. The 200 mg/28.5 mg and 400 mg/57 mg per 5 mL concentrations have approximately 7:1 ratios. These are distinct formulations and should not be compared as though they contain the same proportions of active ingredients.
A higher amoxicillin concentration does not automatically make a bottle a better value. The corresponding clavulanate quantity, prescribed regimen, final volume and suitability for the individual prescription remain important. Patients should not select a different concentration based on cost or attempt to calculate an equivalent volume independently.
A meaningful quotation should preserve the complete concentration, final dispensed volume and actual branded or generic product. If one pharmacy quotes 400 mg/57 mg per 5 mL and another quotes 250 mg/62.5 mg per 5 mL, the amounts do not describe the same medicine concentration, even when the final bottles contain the same volume.
The standard Augmentin suspension guide covers the pharmaceutical characteristics in more detail. This section uses those verified strengths only to establish accurate pricing categories.
| Standard suspension strength | Amoxicillin per 5 mL | Clavulanic acid per 5 mL | Ratio | Cost-comparison requirement |
|---|---|---|---|---|
| 125 mg/31.25 mg per 5 mL | 125 mg | 31.25 mg | 4:1 | Match the complete strength pair and final bottle volume. |
| 200 mg/28.5 mg per 5 mL | 200 mg | 28.5 mg | Approximately 7:1 | Verify the same concentration, quantity and product category. |
| 250 mg/62.5 mg per 5 mL | 250 mg | 62.5 mg | 4:1 | Do not confuse the liquid concentration with a conventional tablet strength. |
| 400 mg/57 mg per 5 mL | 400 mg | 57 mg | Approximately 7:1 | Confirm the exact strength, volume, brand status and payment terms. |
The FDA identifies different final prepared bottle sizes for each standard Augmentin suspension concentration. The 125 mg/31.25 mg and 250 mg/62.5 mg per 5 mL products have labeled 75 mL, 100 mL and 150 mL configurations. The 200 mg/28.5 mg and 400 mg/57 mg per 5 mL products have labeled 50 mL, 75 mL and 100 mL configurations.
These package volumes should be interpreted as final prepared suspension quantities. They are not identical to the amount of water used in the reconstitution process. For example, the FDA specifies less than 100 mL of added water for the labeled 100 mL package of certain concentrations because the dry formulation contributes to the finished volume.
Bottle-size comparisons are useful only when the concentration and commercial product are also identified. A 100 mL bottle of one concentration should not be treated as equivalent to a 100 mL bottle of another concentration. Similarly, a 150 mL package and a 75 mL package contain different prepared quantities even when their concentrations match.
The FDA-labeled configurations are product records rather than guarantees of current retail stock. Generic manufacturers may market different approved packages, and pharmacies can have different sourcing arrangements. The dispensing pharmacy must confirm the actual bottle or quantity associated with the prescription.
The table below uses the FDA-labeled final volumes to establish comparison categories. It does not suggest that a larger bottle should be selected to reduce the unit price or that unused prepared suspension can be stored for future treatment.
| Standard concentration | FDA-labeled final bottle volumes | Relevant pricing distinction |
|---|---|---|
| 125 mg/31.25 mg per 5 mL | 75 mL, 100 mL, 150 mL | Compare quotes at the same concentration and final prepared volume. |
| 200 mg/28.5 mg per 5 mL | 50 mL, 75 mL, 100 mL | Do not compare a smaller bottle directly with a larger one without identifying quantity. |
| 250 mg/62.5 mg per 5 mL | 75 mL, 100 mL, 150 mL | Preserve both ingredient quantities and the original bottle size. |
| 400 mg/57 mg per 5 mL | 50 mL, 75 mL, 100 mL | Confirm concentration, final volume and actual product availability. |
A common source of confusion in oral suspension price comparisons is the difference between final prepared volume and water added during reconstitution. The FDA provides separate values for these quantities because the powder and added water produce the finished suspension. The final labeled bottle size is the relevant package-volume reference for a pricing comparison.
For example, the FDA describes a 75 mL final bottle of 125 mg/31.25 mg per 5 mL suspension prepared with 67 mL of water. For the corresponding 100 mL final bottle, the labeled amount of added water is 90 mL. Neither water quantity should be treated as the volume of medicine available for dispensing.
The differences are not identical across all concentrations. FDA preparation records specify separate water amounts for the 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL product families. This is why a price quotation must use the finished bottle volume rather than a preparation-water figure extracted from a label.
Reconstitution is a controlled dispensing process. The manufacturer specifies how the powder should be prepared to achieve the labeled concentration. Patients and caregivers should not independently alter the amount of water to increase the apparent volume or reduce cost, because that can change the medication concentration.
The FDA also requires prepared suspension to be stored under refrigeration and unused liquid discarded after 10 days. This product-stability limit is important when assessing dispensing quantities, but it does not define the appropriate treatment duration. The prescribed quantity must come from the healthcare professional's instructions.
The prescribed volume of an oral antibiotic suspension is a separate concept from the manufacturer-labeled bottle size. The prescription identifies the intended regimen and quantity, while the pharmacy determines how to dispense the correct approved product under applicable requirements. A manufacturer package may not correspond exactly to the amount of liquid described in a broad online pricing estimate.
A quotation should therefore distinguish the final volume of the approved package from the actual quantity the pharmacy proposes to supply. Some pharmacies may quote an original bottle configuration, while pricing databases may show standardized quantities that need confirmation. The information must be reconciled before comparing costs.
A simple price-per-milliliter figure can describe a verified quotation, but it may be misleading when different concentrations, original package sizes or payment arrangements are involved. The same final liquid volume can contain different quantities of active ingredients depending on the strength. A larger bottle is not automatically a better choice for a particular prescription.
The ten-day discard period after reconstitution also makes unused-volume assumptions inappropriate. Extra prepared liquid cannot be treated as a reusable reserve for later illness. The pharmacist should clarify the amount actually dispensed and any applicable handling requirements.
When quotes differ because of bottle quantity, patients should ask the pharmacy to explain the product and dispensing amount rather than request a different concentration or larger volume without prescriber review. This keeps the comparison aligned with the prescription.
Augmentin oral suspension is supplied as powder that requires correct preparation before administration. The pharmacy normally handles reconstitution as part of the dispensing process and provides instructions appropriate to the product. Whether preparation or a measuring device is reflected in a separate charge depends on the pharmacy's policies and payment arrangements.
A total prescription quotation can include more than the acquisition cost of the medicine. Dispensing arrangements, insurance reimbursement rules and any separately billed services may affect what the patient pays. It would be inaccurate to assume that every U.S. pharmacy adds a standard reconstitution fee or that all such services are free.
The appropriate question is whether the quoted amount covers the prepared medicine and any required dispensing items. A suitable calibrated oral measuring device may be supplied or recommended. Caregivers should not rely on an ordinary household spoon for precise medication measurement.
If a pharmacy itemizes a service charge, it should be identified separately from the cost of the drug product. This allows a meaningful comparison with another pharmacy's total quotation. A lower drug line item does not necessarily mean the entire prescription transaction will cost less.
The pharmacy must ensure that the finished suspension is prepared according to product labeling and that caregivers receive correct instructions. Cost comparisons should not encourage skipping preparation steps, modifying the concentration or preparing the medicine using improvised water measurements.
| Potential quotation component | What to verify | Important qualification |
|---|---|---|
| Drug product | Actual brand or generic suspension, concentration and dispensed volume | Must match the prescribed product. |
| Reconstitution | Whether pharmacy preparation is included in the quoted amount | Do not assume a universal separate preparation fee. |
| Measuring device | Whether an appropriate oral dosing device is supplied and how it is charged | Availability and charges vary by dispensing arrangements. |
| Dispensing or service charge | Any separately identified pharmacy charge | May depend on pharmacy policies and payment terms. |
| Insurance adjustment | Applicable benefit, copay, coinsurance or deductible terms | Patient cost depends on the specific plan and transaction. |
Original branded Augmentin suspension and approved generic amoxicillin/clavulanate liquid products may have different commercial pricing and supply arrangements. The original brand uses the proprietary name Augmentin, while generic products are identified by the established ingredient names. A pharmacy search result using Augmentin as a familiar heading may nevertheless display a generic product.
A reliable cost comparison therefore requires the actual branded or generic designation. The concentration, final prepared volume and package identity must also match. A generic suspension with a different strength pair or bottle size is not an equivalent pricing observation merely because it contains the same two active ingredients.
The FDA Orange Book provides approved product and applicable therapeutic-equivalence information. DailyMed can help identify labelers and package details. Generic manufacturers or repackagers may use different NDCs, which can help explain discrepancies in pharmacy listings without establishing which product is cheapest.
An appropriately approved generic can be dispensed when permitted by the prescription and applicable substitution rules. However, patients should not change concentrations independently or infer that every amoxicillin/clavulanate liquid product is interchangeable. The actual product must be assessed by the pharmacist.
The generic Augmentin price guide covers generic cost factors across dosage forms. The brand Augmentin price guide addresses original brand products more broadly, while generic manufacturer records explains approval holders and labeler identities.
A pharmacy cash quotation, insurance copay and prescription discount-card amount describe different payment arrangements. Each can produce a different patient cost for the same oral suspension. They should not be combined into a single comparison without identifying the payment basis and any applicable restrictions.
Insurance coverage may depend on the plan's formulary, pharmacy network, deductible, copay or coinsurance rules. Original brand Augmentin and generic amoxicillin/clavulanate may be subject to different benefit conditions. Some plans can also distinguish dosage forms or concentrations.
Prescription discount programs may display prices for a default concentration and bottle volume. If those settings do not match the actual prescription, the advertised amount is not a reliable estimate for the intended product. Coupon programs may also have pharmacy-participation or promotional restrictions.
The patient should compare amounts using the same product identity, concentration and dispensed volume whenever possible. A cash amount from one pharmacy cannot be assumed to apply under another pharmacy's discount or insurance terms.
The Augmentin insurance coverage guide addresses the broader benefit framework. This section concentrates on the payment distinctions relevant to oral suspension quotations.
Augmentin ES-600 is a separately labeled pediatric suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL. It has an approximately 14:1 ingredient ratio and distinct FDA-labeled indications. It should not be grouped with the four standard suspension concentrations merely because it is supplied as an oral liquid.
The FDA specifically states that ES-600 is not substitutable with other Augmentin formulations. A pharmacy quotation for standard 400 mg/57 mg per 5 mL suspension is therefore not a quotation for ES-600 and cannot justify a product change. The Augmentin ES-600 guide covers the specialized formulation, while ES-600 vs regular Augmentin explains the comparison in detail.
Conventional Augmentin tablets and chewable tablets have different dosage forms and strength pairs from oral suspension. Although the FDA recognizes certain formulation-switching relationships under specific conditions, patients should not infer that a tablet price can be compared directly with a liquid price as though the products were universally interchangeable.
Augmentin XR uses extended-release tablet technology and has separate substitution restrictions. Its commercial availability and pricing require product-specific verification rather than applying ordinary Augmentin tablet or liquid cost assumptions. The Augmentin XR guide explains this distinction.
These boundaries keep the suspension price page focused on standard liquid packages while avoiding unsupported treatment changes or misleading comparisons across different formulations.
A meaningful comparison begins with an existing valid prescription and a precise identification of the intended liquid. The complete amoxicillin/clavulanate concentration must be confirmed, together with the final prescribed or dispensed volume and whether the original brand or an approved generic is being quoted.
The next step is to identify the actual pharmacy and product. Manufacturer or labeler information and the relevant NDC can help distinguish specific packages. A product's FDA labeling does not guarantee that it is currently stocked, so the pharmacy must confirm whether the prescription can be filled.
Each quotation should identify the payment method, pharmacy location and date. Cash, discount-card and insurance amounts should be compared separately, and any preparation or service charges should be clarified. If one quotation includes a measuring device or preparation service and another does not, the total patient cost may differ.
If the exact prescribed concentration or bottle volume is unavailable, patients should consult the pharmacist and prescriber rather than selecting a different strength. The FDA's formulation and substitution requirements must be respected even when another product appears to have a lower price.
The checklist below provides a durable framework for comparing oral suspension offers without relying on published retail amounts that may become outdated.
| Comparison field | What to verify | Why it matters |
|---|---|---|
| Prescription | Valid prescription identifying the intended combination medicine | Augmentin suspension is prescription-only. |
| Brand or generic | Original Augmentin or the actual approved generic product | Prevents brand and generic price confusion. |
| Concentration | Both active ingredients in mg per 5 mL | Distinguishes the four standard liquid formulations. |
| Final volume | Prepared bottle or dispensed quantity in mL | Separates package size from concentration and added water. |
| Manufacturer and NDC | Actual product or package identification | Helps reconcile different labeled presentations. |
| Preparation and device | Reconstitution status and any applicable device or service charge | Clarifies the scope of the quotation. |
| Pharmacy and location | Dispensing pharmacy, city or ZIP code | Provides geographic pricing context. |
| Payment basis | Cash, insurance or discount terms | Allows consistent comparison of patient costs. |
| Quotation date | Date the terms were confirmed | Helps distinguish current information from older estimates. |
| Supply status | Whether the pharmacy can actually dispense the prescribed product | A listed price does not establish inventory. |
Augmentin suspension is a prescription-only antibacterial medicine in the United States. A low advertised price does not establish that the medicine is appropriate for a particular infection or that a pharmacy may dispense it without a valid prescription. Clinical assessment remains necessary.
The combination contains amoxicillin, a penicillin-class antibacterial, and clavulanate. Patients with relevant allergy histories or other contraindications require professional evaluation. Serious hypersensitivity reactions and other adverse effects are described in the FDA-approved labeling.
Patients and caregivers should not select a different concentration, add extra water to increase bottle volume, reuse leftover prepared suspension or share antibiotics to reduce costs. The prepared liquid must be handled according to the product's storage and discard instructions. These requirements protect medication quality and reduce the risk of dosing errors.
Antibiotics are not effective against viral illnesses such as influenza or the common cold. Unnecessary antibacterial use can expose patients to adverse effects and contribute to antimicrobial resistance.
The penicillin allergy guide provides additional safety context, while the Augmentin online pharmacy guide addresses legitimate prescription-based pharmacy services. This page provides pricing education rather than personalized treatment advice.
There is no single U.S. retail price for Augmentin suspension. Cost depends on the exact concentration, final bottle volume, original brand or generic product, pharmacy, location and payment method. A current pharmacy quotation is needed to establish the applicable amount.
Yes. Standard Augmentin suspension has four strength pairs: 125/31.25, 200/28.5, 250/62.5 and 400/57 mg per 5 mL. Each is a distinct concentration, so quotations should identify both active ingredients and should not combine different strengths as though they were identical.
FDA labeling identifies 75, 100 and 150 mL final bottles for the 125/31.25 and 250/62.5 mg per 5 mL concentrations. It identifies 50, 75 and 100 mL final bottles for the 200/28.5 and 400/57 mg per 5 mL concentrations. These records do not guarantee current pharmacy inventory.
No. A 100 mL bottle describes the final prepared volume, not the active-ingredient concentration. Different Augmentin suspension strengths can be supplied in 100 mL bottles and contain different amounts and proportions of amoxicillin and clavulanic acid.
Not necessarily. Unit pricing depends on the exact concentration, product, pharmacy and payment arrangement. A larger bottle is also not automatically appropriate for a prescription, and unused prepared suspension cannot be saved indefinitely.
No. The FDA specifies separate amounts of water for reconstitution and final prepared bottle volumes. The final labeled volume includes the prepared suspension and should be used to identify the package quantity in a pricing comparison.
Not universally. Pharmacy preparation may be included in the prescription charge or reflected in the pharmacy's dispensing arrangements. Any separately billed preparation or service charge should be confirmed with the pharmacy rather than assumed.
This depends on the dispensing pharmacy and applicable payment arrangements. Patients should confirm whether an appropriate calibrated measuring device is supplied and whether any separate charge applies.
Generic and original branded products may have different commercial costs, but no universal difference can be guaranteed without comparable current quotations. The concentration, final volume, pharmacy and payment method must match before evaluating a price difference.
Prices may vary because of the actual product, manufacturer or labeler, bottle volume, sourcing arrangements, preparation and dispensing terms, pharmacy location and payment method. A quotation from one pharmacy does not establish a nationwide price.
Their products and pricing factors can be described separately, but they should not be treated as equivalent pharmacy offers. Different concentrations contain different active-component amounts, and patients should not switch strengths independently based on cost.
No such pricing relationship should be assumed. ES-600 is a separately labeled pediatric suspension containing 600 mg/42.9 mg per 5 mL. Its formulation and FDA substitution restrictions differ from standard Augmentin liquids, so its price and availability require separate verification.
Coverage depends on the insurance plan, specific branded or generic product, concentration, pharmacy network and applicable cost-sharing requirements. A pharmacy or insurer must verify the patient's actual coverage and out-of-pocket amount.
Some discount programs may offer eligible pricing for amoxicillin/clavulanate suspension, but the actual terms depend on the product, concentration, bottle volume and participating pharmacy. A displayed discount does not guarantee a particular transaction price.
Confirm the complete strength pair in mg per 5 mL, final prepared volume, brand or generic status, actual product, pharmacy location, quotation date and payment method. Ask whether preparation, an appropriate measuring device and other dispensing items are included.
No. FDA product listings, NDCs and published pharmacy price estimates do not establish real-time stock. The pharmacy must confirm whether the exact prescribed concentration and quantity can be dispensed.
Patients and caregivers should not independently change concentrations or calculate substitute liquid volumes. Augmentin formulations contain different amounts and proportions of active ingredients, and any proposed change requires professional assessment.
No. Augmentin suspension is a prescription-only antibacterial medicine in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements.